Colorectal Cancer
Conditions
Keywords
stage III rectal cancer, stage IV rectal cancer, adenocarcinoma of the rectum
Brief summary
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as capecitabine, oxaliplatin, fluorouracil, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving radiation therapy together with combination chemotherapy and cetuximab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving chemotherapy and cetuximab after surgery may kill any tumor cells that remain after surgery. PURPOSE: This phase II clinical trial is studying how well giving radiation therapy together with chemotherapy and cetuximab followed by surgery, chemotherapy, and cetuximab works in treating patients with locally advanced or metastatic rectal cancer that can be removed by surgery.
Detailed description
OBJECTIVES: Primary * Determine the complete remission rate at 6 months after neoadjuvant radiotherapy, capecitabine, and oxaliplatin (XELOX), and cetuximab followed by surgery, adjuvant FOLFOX 4, and cetuximab in patients with synchronous locally advanced or metastatic cancer of the rectum with resectable metastases (T3-4 Nx or T2 N+ M1). Secondary * Determine progression-free survival. * Determine overall survival. * Assess toxicities. * Evaluate objective response in patients with measurable metastases. * Determine the rate of local recurrence. * Evaluate the downstaging and downsizing of patients with operable disease. * Evaluate surgical complications in patients with operable disease. * Evaluate biological markers predictive of response to cetuximab. OUTLINE: This is a multicenter study. * Neoadjuvant therapy: Patients undergo radiotherapy for 5 weeks and receive concurrent oral capecitabine twice daily on days 1-5 of each week and oxaliplatin IV over 2 hours on day 1 of each week (XELOX). Patients also receive cetuximab IV on day 1 of the first week and on days 1-7 of weeks 2-5. * Surgery: At 6 weeks after completing chemoradiotherapy, patients with resectable disease undergo surgery comprising total mesorectal excision. Patients with progressive disease, nonresectable tumor, or who require R2 surgery are removed from the study. * Adjuvant therapy: Patients who undergo surgery, with or without removal of metastases, receive FOLFOX 4, comprising oxaliplatin IV over 2 hours, fluorouracil IV over 46 hours, and leucovorin calcium IV on day 1, and cetuximab IV. Treatment repeats every 2 weeks for up to 6 courses (approximately 3 months). Patients who have not undergone prior surgical resection of metastases may have surgery to remove metastases after completing this second regimen of chemotherapy. After completion of study therapy, patients are followed periodically for up to 5 years.
Interventions
BIOLOGICALcetuximab
DRUGcapecitabine
DRUGfluorouracil
DRUGleucovorin calcium
DRUGoxaliplatin
PROCEDUREadjuvant therapy
PROCEDUREconventional surgery
PROCEDUREneoadjuvant therapy
RADIATIONradiation therapy
Sponsors
UNICANCER
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Histologically confirmed adenocarcinoma of the rectum * Locally advanced (T3-4 Nx) or metastatic (T2 N+ M1) synchronous disease * Metastases must be resectable * Primary tumor examined by endorectal echography and MRI * Measurable disease by thoraco-abdomino-pelvic scanner * Disease considered susceptible to treatment with radiotherapy and chemotherapy * No diffuse metastases considered nonresectable * No acute occlusion not caused by colostomy PATIENT CHARACTERISTICS: Inclusion criteria: * ECOG performance status 0-2 * WBC ≥ 4,000/mm\^3 * Absolute neutrophil count ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Hemoglobin ≥ 10 g/dL * Creatinine ≤ 130 µmol/L * Transaminases ≤ 5 times upper limit of normal (ULN) * Total bilirubin ≤ 1.5 times ULN * Alkaline phosphatase ≤ 2.5 times ULN * Not pregnant or nursing * Negative pregnancy test * Fertile patients of must use effective contraception
Exclusion criteria
* Contraindication to therapy with capecitabine, oxaliplatin, cetuximab, and/or radiotherapy * Impossible to perform translational analyses * Uncontrolled severe illness * Severe renal or hepatic insufficiency * Cardiac insufficiency or symptomatic coronary disease * Sensitive peripheral neuropathy * Uncontrolled diabetes * Other malignancy within the past 10 years except previously treated basal cell skin cancer or carcinoma in situ of the cervix * Impossible to participate in study due to geographic, social, or psychiatric reasons * Patients who are under supervision or incarcerated PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No prior anticancer chemotherapy or radiotherapy for this cancer * No therapy with coumarin anticoagulants, phenytoin, sorivudine, brivudine, antacids, or allopurinol * No concurrent participation in another therapeutic study or receiving another experimental drug
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete remission at ≥ 6 months by abdomino-pelvic-thoracic scan and a pelvic MRI | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival | — |
| Overall survival | — |
| Early toxicity before surgery | — |
| Early toxicity due to surgery (mortality at 30 days, postoperative complications, surgical recovery) | — |
| Late toxicity | — |
| Late radiotherapy toxicity by CTC AE v. 3.0 | — |
| Preoperative clinical response | — |
| Sexual function | — |
| Downstaging and downsizing of patients with operable disease | — |
| Surgical complications | — |
| Sphincter function | — |
| Predictive biomarkers of response to cetuximab | — |
| Objective response of measurable metastases by RECIST | — |
Countries
France
Outcome results
None listed